GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex, GW’s can... more
GW Pharmaceuticals plc (AIM: GWP) today announces that it has started a new Phase III trial of Sativex® in Multiple Sclerosis (MS) Spasticity. This trial is designed to resolve the outstanding issue a... more
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announced that the first US Phase II/III dose-ranging trial has been initiated to evaluate the efficacy and safety of Sative... more
GW Pharmaceuticals plc (AIM: GWP) today announces that The International Association of the Study of Pain has published online the results of a study in its official journal Pain, showing that Sativex... more
GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled “randomized withdrawal” study of Sativex® in patients with neuropathic pain due to Multiple Sclerosis (MS).... more
GW Pharmaceuticals plc (AIM: GWP) and Bayer HealthCare Pharmaceuticals announce that Health Canada, the Canadian regulatory agency, has issued a Qualifying Notice for the approval of Sativex® in the r... more
GW Pharmaceuticals plc (AIM: GWP) today announces that the Journal of Clinical Therapeutics has published the results of a study which show that Sativex® provides effective long term treatment of cent... more
GW Pharmaceuticals plc (AIM: GWP) announces that patient recruitment is now complete in its pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain.... more
GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announce that Health Canada has approved Sativex®, a cannabis derived pharmaceutical treatment, as adjunctive analgesi... more
GW Pharmaceuticals plc and Otsuka Pharmaceutical Co., Ltd today announce a major long term strategic cannabis alliance. An exclusive licence and development agreement has been signed for Sativex® in t... more
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2007. ... more
GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders... more
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co. Ltd today announce that they have each received early termination by the United States Federal Trade Commission and the Antitrust Divisi... more
GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Mr Richard Forrest as a non-executive director. Mr Forrest replaces Mr David Morrison who is standing down from the Board with effe... more
GW Pharmaceuticals plc (AIM: GWP) a leading neurology journal, The European Journal of Neurology, today reports a study showing that Sativex significantly reduces intractable spasticity (spasms and st... more
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance.... more
Porton Down, UK, 30 January 2007: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for t... more
Porton Down, UK, 26 January 2007: GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment of James Noble as an independent non-executive director with immediate effect. James has also... more
GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain. These studies are part of a prog... more
